Pembrolizumab, an immuno-oncological medicine, is included in the approved List of Vital and Essential Drugs (VED) for 2018.
“This is an important step to make the latest immuno-oncological technology available within the programs of state guarantees for patients with metastatic melanoma and lung cancer,” said Marwan Akar, the General Manager of MSD in Russia. “We welcome the inclusion of pembrolizumab in the VED List. In order to let it help increase the length and quality of life for as many patients with appropriate indications as possible, we focus on active collaboration with the government authorities, scientific and medical community, and patient organizations.”
Earlier, the commission of the Ministry of Health in charge of preparing the lists of medicinal products for human use decided to include pembrolizumab in the VED List. This decision was based on the data about clinical and economic efficiency of pembrolizumab for the treatment of metastatic melanoma and advanced PD-L1-positive non-small-cell lung cancer.
Pembrolizumab was developed by MSD and for the first time registered in Russia in November 2016.